Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series.
1/5 보강
Synthetic lethality has proven to be a tactical paradigm to design synergistic anticancer drug combinations.
APA
Ferrandi G, Bagnolini G, et al. (2026). Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series.. ACS medicinal chemistry letters, 17(2), 520-530. https://doi.org/10.1021/acsmedchemlett.5c00711
MLA
Ferrandi G, et al.. "Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series.." ACS medicinal chemistry letters, vol. 17, no. 2, 2026, pp. 520-530.
PMID
41704388 ↗
Abstract 한글 요약
Synthetic lethality has proven to be a tactical paradigm to design synergistic anticancer drug combinations. In this context, we leveraged BRCA2 and PARP as a synthetic lethal target pair to consolidate the use of small molecule inhibitors of RAD51-BRCA2 protein-protein interaction as inducers of the BRCAness phenotype that sensitizes -functional cancer cells to PARP inhibitors. Starting from compound , a phenyl furan-carboxyquinoline, we developed a series of analogues, leading to derivative . This compound effectively inhibits RAD51-BRCA2 interaction, impairs homologous recombination, and synergizes with olaparib in BxPC-3 pancreatic cancer cells, inducing synthetic lethality in both 2D and 3D spheroids. Additionally, showed efficacy in human pancreatic cancer cells and no toxicity in normal pancreatic cells, positioning it as an early tool compound and a starting point for further optimization.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Editorial: Altered metabolic traits in gastro-intestinal tract cancers, volume II.
- Racial Disparities in Pancreatic Cancer: A Comprehensive Population-Based Analysis of Survival, Surgical Access, and Prognostic Factors.
- Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.